A federal grand jury indicted Berkeley Premium Nutraceuticals, the company's President Steve Warshak, his mother and five additional defendants and co-conspirators on a total of 112 criminal charges Sept. 20. Warshak engaged in conspiracy to commit mail, wire and bank fraud, money laundering, conspiracy to obstruct proceedings before FTC and other criminal acts, U.S. Attorney for the Southern District of Ohio Gregory Lockhart alleges. Warshak, et al., defrauded consumers of more than $100 mil., according to Lockhart. If convicted, the defendants are expected to forfeit assets including several parcels of land, vehicles, and the contents of numerous bank and investment accounts, according to the filing. Berkeley, marketer of male enhancement supplement Enzyte, settled with the Attorney Generals of six states in March for $2.5 mil. (1"The Tan Sheet" March 6, 2006, p. 8). Earlier this month, the Cincinnati, Ohio-based firm issued a press release asserting they had reduced consumer complaints by 90% (2"The Tan Sheet" Sept. 11, 2006, In Brief)....

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.